[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].

Alexey Boyko O V Boyko K Z Bakhtiyarova E I Gusev V A Dudin L G Zaslavsky N A Malkova Ye V Parshina I Ye Poverennova Stella Sivertseva N A Totolyan S G Shchur A S Fedulov F A Khabirov D D Bolsun Arina V Zinkina-Orikhan Yulia N LinkovaT V Chernovskaya

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)

The new drug samPEG-IFN-β1a is an effective and safe agent for relapsing remitting multiple sclerosis treatment, while having an advantage over other low-dose interferons in the form of reduced frequency of intramuscular injections.

Keyphrases

multiple sclerosis
clinical trial
low dose
white matter
disease activity
emergency department
immune response
randomized controlled trial
systemic lupus erythematosus
study protocol
mesenchymal stem cells
bone marrow
replacement therapy
open label
smoking cessation